Sanofi-Aventis's Lantus insulin linked to cancer risk in studies
30 June 2009
Malini Guha
Please Login to read the full article.
30 June 2009
Malini Guha
Sanofi-Aventis's long-acting (once-daily) insulin analogue Lantus (insulin glargine), one of its best-selling drugs, has been linked to an increased risk of cancer compared with human insulin in analysis of data from patient registries in several European countries, and while the data...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Novo Nordisk to begin Phase IIIa for Degludec-Victoza combination in diabetes
- Sanofi-Aventis opts out of diabetes deal with Metabolex
- Novo Nordisk to file Lantus rival Degludec in US after EU
- Sanofi results: Genzyme doesn't paper over cracks, as emerging markets top US and EU
COMMENT
Other Informa Comment
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
